9 abril 2015
Well intentioned, but costly and potentially problematic. That’s how researchers describe the end result of a decision by the Food and Drug Administration (FDA) to regulate colchicine, a drug used to treat gout, among other ailments. Fewer patients are actually now taking it, and it has come at a cost to their wallets, says the study’s leader. Colchicine had been sold at low cost for many years in the US. It is widely used to treat gout, and is the primary treatment for a rare inflammatory disease called familial Mediterranean fever.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/3GfCDJnA_o4/150409094022.htm
